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Hyaluronan synthase 1 (HAS1) is one of three isoenzymes responsible for cellular hyaluro-
nan synthesis. Interest in HAS1 has been limited because its role in hyaluronan production
seems to be insignificant compared to the two other isoenzymes, HAS2 and HAS3, which
have higher enzymatic activity. Furthermore, in most cell types studied so far, the expres-
sion of its gene is low and the enzyme requires high concentrations of sugar precursors
for hyaluronan synthesis, even when overexpressed in cell cultures. Both expression and
activity of HAS1 are induced by pro-inflammatory factors like interleukins and cytokines,
suggesting its involvement in inflammatory conditions. Has1 is upregulated in states asso-
ciated with inflammation, like atherosclerosis, osteoarthritis, and infectious lung disease.
In addition, both full length and splice variants of HAS1 are expressed in malignancies like
bladder and prostate cancers, multiple myeloma, and malignant mesothelioma. Interest-
ingly, immunostainings of tissue sections have demonstrated the role of HAS1 as a poor
predictor in breast cancer, and is correlated with high relapse rate and short overall survival.
Utilization of fluorescently tagged proteins has revealed the intracellular distribution pattern
of HAS1, distinct from other isoenzymes. In all cell types studied so far, a high proportion of
HAS1 is accumulated intracellularly, with a faint signal detected on the plasma membrane
and its protrusions. Furthermore, the pericellular hyaluronan coat produced by HAS1 is
usually thin without induction by inflammatory agents or glycemic stress and depends on
CD44–HA interactions. These specific interactions regulate the organization of hyaluronan
into a leukocyte recruiting matrix during inflammatory responses. Despite the apparently
minor enzymatic activity of HAS1 under normal conditions, it may be an important factor
under conditions associated with glycemic stress like metabolic syndrome, inflammation,
and cancer.
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INTRODUCTION
Hyaluronan is the most abundant matrix polysaccharide, which
maintains tissue homeostasis, gives compressive strength for tis-
sues, acts as an ideal lubricant in body fluids and accelerates growth
and healing. In addition, excess hyaluronan promotes cancer
progression and mediates inflammation. Therefore, membrane-
bound hyaluronan synthases (HAS1–3), special enzymes respon-
sible for hyaluronan production, have a key role in regulation
of these conditions. Despite highly homologous amino acid
sequences, HAS’s differ in subcellular localization, enzymatic
activity, and regulation (1).
Despite almost 20 years of active research to sequence hyaluro-
nan synthase genes, it is not known why vertebrates have three
different isoforms of these enzymes, which are coded by separate
genes on different chromosomes, to synthesize a single sugar poly-
mer. Most research has focused on HAS2 and HAS3, while HAS1
has received the least attention and remains the most enigmatic,
with only a few published reports of its biological effects on cellular
behavior or association with disease states.
Knocking out the activity of hyaluronan synthase genes has
provided a better understanding about normal HAS function.
Knockout of Has2 results in embryonic lethality with severe car-
diac and vascular malformations (2), while the knockout of Has1
or Has3 does not have any apparent phenotype under non-stressed
conditions (3, 4). However, double knockout of Has1 and Has3
leads to enhanced inflammation and accelerated wound closure
of mouse skin (5), suggesting that they are necessary for the
regulation of acute inflammation following injury.
A number of recent studies have highlighted the role of HAS1
in health and disease. Interestingly, Has1 was the most upreg-
ulated gene in aneuploid mouse embryonic fibroblasts (MEFs)
with malignant properties (6) and splice variants of HAS1 are sug-
gested to contribute to genetic instability (7), suggesting that it
is susceptible to genetic alterations during oncogenic transforma-
tion. Surprisingly, HAS1 immunostainings of breast carcinoma
cells correlated with hyaluronan staining, estrogen receptor nega-
tivity, HER2 positivity, high relapse rate, and short overall survival.
In stromal cells of tumors from the same patients, the staining level
of HAS1 was related to obesity and large tumor size (8). Human
mesenchymal stem cells from different donors express HAS1 in
variable but significant levels (9), suggesting its contribution to
formation of a hyaluronan niche that maintains stemness of the
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cells. HAS1 is upregulated during human keratinocyte differentia-
tion (10) and its expression correlates with levels of HA synthesis,
indicating that HAS1 is an important regulator of skin home-
ostasis. Furthermore, as compared to other isoforms, differences
in HAS1 substrate requirements (11–13), subcellular localization,
and the structure of the hyaluronan coat (7, 13, 14) have been
reported, suggesting an independent role of HAS1 in the regu-
lation of cell and tissue homeostasis. However, a comprehensive
review of HAS1 has not been published. Therefore, the purpose
of this review is to summarize and discuss the current knowledge
of this mysterious enzyme. In this review, the abbreviations Has1
and Has1 are used for non-human gene and protein, and HAS1
and HAS1 for human gene and protein, respectively.
GENETICS AND FUNCTION OF Has1 GENES AND PROTEINS
Hyaluronan is synthesized by HAS enzymes found in vertebrates,
some bacteria, and a virus (15). The first Has was cloned in Group
A Streptococcus pyogenes and it was predicted to be an integral
membrane protein (16). The first human HAS gene was isolated
by two research groups almost simultaneously. Shyjan and co-
workers used functional expression cloning in Chinese hamster
ovary (CHO)-cells (17) and Itano and Kimata screened cDNA
libraries of human fetal brain (18).
Mammalian cells have three distinct synthase genes, Has1-3
(the human genes are abbreviated here as HAS1-3). They are well-
conserved with highly homologous amino acid sequences, but
located on separate chromosomes. In humans, HAS1 resides in
chromosome 19 at q13.3–13.4, HAS2 is located in chromosome
8 at q24.12 and HAS3 is in chromosome 16 at q22.1 (19). HAS1
gene has five exons, whereas HAS2 and HAS3 both have four (20).
Several alternative splice variants of HAS1 have been reported in
Waldenström’s macroglobulinemia (21), multiple myeloma (22),
and bladder cancer (23). In silico, the HAS1 gene has 46 pos-
sible transcription-factor binding sites 500 bp upstream of the
transcription start site (20).
Has1 is not essential for embryogenesis. Has2 knockout mice
die at embryonic day 9.5 due to cardiovascular defects (2), but mice
deficient in Has1 (3) or Has3 (4) are viable and fertile. Further-
more, double knockout Has1 and Has3 mice have been developed
and are phenotypically normal (5).
The three hyaluronan synthase proteins in humans are des-
ignated as HAS1, HAS2, and HAS3. Mammalian hyaluronan
synthases are integral membrane proteins with 4–6 transmem-
brane domains in addition to 1–2 membrane-associated domains
(15, 24). The synthase enzymes need Mg2+ or Mn2+ to produce
hyaluronan, in addition to the uridine diphosphate (UDP) sugar
precursors, UDP–glucuronic acid (UDP–GlcUA), and UDP–N -
acetylglucosamine (UDP–GlcNAc) (15, 25) The synthesis takes
place at the inner surface of the plasma membrane utilizing cyto-
plasmic precursors (26). Human and mouse enzymes add the
precursor sugars to the reducing end of the growing polymer (27–
29), while amphibian Xenopus laevis Has utilizes the non-reducing
end (30), like the Pasteurella multocida hyaluronan synthase (31).
It has been suggested that the HAS enzymes do not require
any primers for the synthesis of hyaluronan (32). The adenosine
triphosphate-binding cassette (ABC) transporters have been pro-
posed to be important for hyaluronan translocation on the plasma
membrane of fibroblasts (33), requiring a concurrent efflux of
K+ ions (34). However, ABC transporters do not seem to con-
tribute to the translocation of hyaluronan in breast cancer cells
(35). The Has protein has been shown to produce hyaluronan in
a combined process of synthesis and membrane translocation, as
demonstrated by Has reconstituted into proteoliposomes in Strep-
tococcus equisimilis (Se) (36). In addition, there is an intraprotein
pore in Has and the synthase itself is able to translocate hyaluronan
in liposomes containing purified Se-Has (37).
REGULATION OF HAS1 EXPRESSION AND ACTIVITY
The three HAS genes are often regulated in parallel (38, 39) and
the synthesis of hyaluronan reflects changes at the mRNA level
(40–44). HAS1 expression is transcriptionally regulated by trans-
forming growth factor-β (TGF-β) in synoviocytes (45, 46) and by
the pro-inflammatory cytokine interleukin-1β (IL-1β) in fibrob-
lasts (44, 47, 48), while these factors may have similar or opposite
effects on other HASs, depending on cell type. The nuclear factor
kappa B (NF-κB) (49) and tyrosine kinases (50) have been shown
to be important for IL-1β-induced HAS1 activation, while induc-
tion of HAS1 by TGF-β seems to act through the p38 MAPK path-
way (51). There is evidence that some of the effects are mediated
by transcription-factors sp1 (52) and sp3 (53). Table 1 summa-
rizes the growth factors and cytokines that regulate Has1/HAS1
expression. In addition to these factors, ultraviolet B radiation
induces a fast up-regulation of Has1 expression in rat epidermal
Table 1 |Transcriptional regulation of Has1/HAS1 by different growth
factors and cytokines (↑ increased, ↓ decreased).
Agent Cell/tissue HAS1 Reference
EGF Human fibroblast ↑ (44)
EGF Human oral mucosal cell ↑ (44)
FGF2 Human dental pulp ↑ (58)
FGF2 Human periodontal ligament ↑ (59)
FGF Human fibroblast ↑ (60)
Forskolin Human orbital fibroblast ↑ (48)
IGF Human fibroblast ↑ (60)
IL-1β Human fibroblast ↑ (44)
IL-1β Human fibroblast ↑ (61)
IL-1β Murine uterine fibroblast ↑ (47)
IL-1β Human orbital fibroblast ↑ (48)
IL-1β Human dermal fibroblast ↑ (53)
PDGF Human fibroblast ↑ (62)
Progesterone Murine uterine fibroblast ↓ (47)
Prostaglandin D2 Human orbital fibroblast ↑ (63)
Prostaglandin E2 Human synoviocyte ↑ (64)
TGF-β Human fibroblast ↑ (65)
TGF-β Human keratinocyte ↑ (65)
TGF-β Human synoviocyte ↑ (46)
TGF-β Human synoviocyte ↑ (45)
TGF-β Human dermal fibroblast ↑ (53)
Estradiol Human vascular smooth muscle cell ↓ (66)
4-MU Human aortic smooth muscle cell ↓ (67)
TGF-β1 Human synoviocyte ↓ (68)
TGF-β Human mesothelial cell ↑ (40)
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keratinocytes (54). Additionally, Has1 expression levels are raised
in renal (55) and pulmonary (56) ischemia and hyperglycemia
(57). The synthesis of hyaluronan by HAS1 is also regulated by
the substrate concentrations of the precursor sugars (discussed in
detail later in this review).
There is evidence that the activities of HAS2 and HAS3 are
regulated by posttranslational modifications like phosphorylation
(38, 69), ubiquitination (70), or O-GlcNAcylation (71). Whether
these modifications are involved in the regulation of HAS1 activity
is not completely known. Phosphorylation seems not to regulate
HAS1 activation (72), but HAS1 can exist in multimers of full
length-HAS1 or its variants, formed by intermolecular disulfide
bonds (73).
The reported length of hyaluronan polymers produced by
each of the mammalian Has differs, but the obtained results
vary depending on the experimental set-up (74–77). For exam-
ple, in membrane preparations from CHO-cells transfected with
recombinant Has isoforms, Has2 produced the largest hyaluronan
(over 3.9× 106 Da), Has3 produced intermediate length hyaluro-
nan (0.12–1× 106 Da), and HAS1 produced the smallest polymer
(0.12× 106 Da). However, all isoforms produced high molecular
weight hyaluronan (3.9× 106 Da) in live cells (76). The size of the
growing hyaluronan chain is increased or decreased by mutation
of certain cysteine or serine amino acids in the Has1 protein in X.
laevis, suggesting that the size of the hyaluronan chain is affected
by the ability of the synthase to bind it (74).
SUBCELLULAR LOCALIZATION AND TRAFFIC OF HAS1 AND
ITS IMPACT ON FORMATION OF HA-COAT
Our understanding of the localization and traffic of Has pro-
teins has been deepened after recruitment of fluorescent HAS
fusion proteins together with live cell imaging (78–80). All studies
reported so far suggest that like other Has/HAS isoforms, Has1 fol-
lows the normal intracellular route from rER to Golgi (78), and its
traffic is regulated similarly to other HAS isoforms (13), as shown
by manipulation of its traffic in live cells by factors like 4-MU and
brefeldin A (BFA).
A typical subcellular localization pattern of GFP-HAS1 is pre-
sented in Figure 1. The GFP–HAS1 signal is mainly cytoplasmic,
rather than on the plasma membrane, being distributed either dif-
fusely or in cytoplasmic patches, and partially co-localizing with
the Golgi apparatus (13, 14, 73). Only a small proportion of the
total cellular pool of HAS1 is located on the plasma membrane,
even when activated with glucosamine (12), or inflammatory
cytokines like TNF-α or IL-1β (13). Occasionally, HAS1 signal is
seen on or near the plasma membrane, usually as patches or con-
centrated spots (arrows in Figure 1), or on the plasma membrane
protrusions (13, 14). The low plasma membrane signal of HAS1 is
in parallel with the low activity level of HAS1, because latent HAS
enzymes are thought to stay in the ER–Golgi compartment.
In addition to the full-length form, HAS1 has multiple tran-
script variants resulting from alternative splicing. Transfected
HAS1V–GFP constructs localize with cytoskeletal structures like
microtubules (7, 73). The reticular localization of the standard
form of HAS1 (Figures 1 and 2) suggests that all forms of HAS1
studied so far are associated with the cytoskeletal network or endo-
plasmic reticulum, which is a distribution that is not typical for
HAS2 or HAS3, and indicates different regulation and binding
partners.
The size of the pericellular hyaluronan coat correlates with
activity of hyaluronan synthesis. Interestingly, even high over-
expression of HAS1 in cell types with little or no endogenous
hyaluronan production is not enough to produce a clearly visible
hyaluronan coat (12, 13, 76). Furthermore, like previously pub-
lished (12–14), the coat produced by HAS1 has a clearly different,
more“cloudy”structure (Figures 1 and 2), as compared to the tight
and concentrated coat around plasma membrane protrusions pro-
duced by HAS2, and especially HAS3 (Figure 2). However, the size
of the coat produced by HAS1 can be induced upon induction
by inflammatory agents or glucosamine (12, 13). The effect of
FIGURE 1 | Intracellular localization of GFP–HAS1 and structure of
pericellular hyaluronan coat induced by GFP–HAS1 overexpression.
Confocal optical sections of live MCF-7 breast cancer cells transfected
with EGFP–HAS1 (green) and stained with fHABC to visualize the
hyaluronan coat (red). Localization of EGFP–HAS1 is shown in
(A), fHABC in (B), and merged images in (C). Arrows in (A) point patches
of signal near the plasma membrane. Scale bar 10µm. Original data
published in Ref. (13).
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FIGURE 2 | Comparison of the structure and intensity of the
pericellular hyaluronan coat in MCF-7 cells overexpressing the three
HAS isoenzymes. Structure of the hyaluronan coat of live MCF-7 cells
transfected with fusion proteins Dendra2–HAS1 (A,D), Dendra2–HAS2
(B,E), and Dendra2–HAS3 (C,F) and labeled with fHABC (red). Single
confocal sections obtained from the middle level of nucleus (blue) are
shown in (A–C). Vertical views created from compressed image stacks of
horizontal optical sections are shown in (D–F) to show the dorsal
protrusions (arrows). The integrated intensity (mean intensity× area) of
hyaluronan coat probed with fHABC in the three HAS transfectants was
measured in thresholded area of optical sections through the center of
nucleus (G). Mean of three independent experiments is represented (total
number of measured cells in each group=92). Magnification bar in (F),
10µm. Original data published in Ref. (12, 81).
glucosamine is presented in Figure 3. Additionally, the hyaluro-
nan coat synthesized by HAS1 is largely dependent on hyaluronan
interactions with CD44 (13).
Detailed studies on tissue distribution and subcellular local-
ization of endogenous HAS’s have been challenging due to the
lack of reliable antibodies and apparently low expression level
of HAS’s in many cell types. Subcellular localization of endoge-
nous HAS1 detected with affinity purified polyclonal antibodies
shows a similar pattern to exogenously expressed HAS1 fusion
proteins (14). HAS1 immunostainings have shown notable levels
of HAS1 in mesothelial cells, fibroblasts (14), and human chon-
drosarcoma cells (9). Furthermore, MEFs have prominent Has1
staining (6). Examples of HAS1 immunostainings in cultured cells
are summarized in Figure 4. These results are in line with the
notable mRNA levels of Has1/HAS1 observed in these cell types
(6, 12, 13).
Staining patterns of HAS1 in tissue sections is in line with cell
culture studies. Immunostainings of Has1 in developing tissues
(14) and HAS1 in tumor tissues (8, 82–85), endometrium (86),
and oral mucosa (87) have been published recently. In tumor tis-
sues, HAS1 is typically expressed in tumor cells (8, 83–85), as well
as in stromal fibroblasts (Figure 5). The localization of HAS1 is
mainly intracellular, corresponding to the staining observed in cell
cultures. Typical staining patterns vary from diffuse to granular
with deposits next to the nucleus, which suggests HAS1 accumu-
lation in the Golgi area (arrowheads in Figure 5), similar to that
seen in cell cultures.
HAS1 REQUIRES HIGH CELLULAR CONTENT OF UDP-SUGARS
FOR ACTIVATION
An important factor affecting activity of all HAS enzymes is the
cytoplasmic availability of substrates, namely, UDP–GlcUA and
UDP–GlcNAc. Many studies have shown that treatments influenc-
ing either UDP–GlcUA or UDP–GlcNAc levels regulate hyaluro-
nan production [reviewed by Vigetti et al. (88)]. This role of
substrates is particularly interesting in regulation of HAS1 as its
activity of hyaluronan production in many cell models is low or
absent unless stimulated.
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FIGURE 3 | Glucosamine induces the growth of hyaluronan coat
produced by HAS1. Confocal optical sections of pericellular hyaluronan coats
on COS-1 cells expressing Dendra2–HAS1 without glucosamine (A–C) and
after 6 h incubation with 1 mM glucosamine (D–F). Green, Dendra2–HAS1;
red, hyaluronan coat; blue, nuclei. Magnification bars 20µm. Original data
published in Ref. (12, 13).
FIGURE 4 | Subcellular localization of endogenous HAS1 detected by
immunostainings. MCF-7 cells transiently transfected with empty vector
(A) and HAS1 expressing plasmid (B), followed by immunostaining with
polyclonal HAS1 antibodies (brown color). Arrows in (B) show the HAS1
overexpressing cells. A 3D confocal projection of human chondrosarcoma
cell (HCS) (C) and transformed mouse embryonic fibroblast (MEF) (D)
stained with HAS1 immunofluorescence (green). Arrows in (C,D) point
plasma membrane protrusions. Blue, nuclei. Magnification bars in
(B,D)=20µm. Original data published in Ref. (6, 9, 14).
FIGURE 5 | Localization of HAS1 in breast cancer tissue. A paraffin
section of breast carcinoma immunostained with HAS1 polyclonal antibody
(brown). Nuclei are labeled blue. A mainly cytoplasmic localization of HAS1
is detected in carcinoma cells (asterisks) and in stromal fibroblasts (arrows).
Special accumulation of staining is seen intracellularly (arrowheads).
Magnification bar 50µm. Original data published in Ref. (8).
In order to study the effect of UDP–GlcUA on hyaluro-
nan production, 4-methylumbelliferone (4-MU) and overex-
pression of enzymes involved in either UDP-Glucose (UDP-
glucose pyrophosphorylase) or UDP–GlcUA (UDP–glucose
6-dehydrogenase) production have mainly been used (39, 89, 90).
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These reports rely mostly on mRNA data to explain the altered
hyaluronan production. The effect of UDP–GlcUA fluctuations
on HAS1–3 expression levels vary considerably from one cell line
to another and it is often impossible to reveal the exact role of
HAS1 during these changes. A recent investigation demonstrated
that availability of UDP–GlcUA can have a direct effect on HAS1
activity, as treatment of MCF-7 cells overexpressing HAS1 with an
inducing agent and 4-MU significantly decrease hyaluronan coat
compared to cells treated with the inducing agent only (13). It has
been reported that Has1 has a lower affinity for UDP–GlcUA than
other Has’s, and the Km of Has1 is about double that of Has2–3.
Interestingly, availability of the other substrate, UDP–GlcNAc, did
not considerably influence the Km of Has1 toward UDP–GlcUA,
whereas levels of UDP–GlcUA did have a significant effect of the
Km toward UDP–GlcNAc (11).
The affinity of Has1 for UDP–GlcNAc is lower than the affinity
of Has2–3 as with UDP–GlcUA. The Km toward UDP–GlcNAc of
Has1 is about two to three times higher that of the other Has’s.
Interestingly, all Has enzymes exhibit lower affinity toward UDP–
GlcNAc than for UDP–GlcUA (11). Treatments with compounds
like mannose and glucosamine that regulate UDP–GlcNAc content
also affect cellular hyaluronan secretion levels (12, 91). Simi-
lar to the level of UDP–GlcUA, the availability of UDP–GlcNAc
influences both mRNA levels and activity of all HAS’s. The differ-
ences in substrate affinities are well demonstrated in intact cells
using HAS1 overexpressing cell lines. Both COS-1 and MCF-7
cell lines have negligible endogenous hyaluronan production, and
even overexpression of HAS1 enzymes does not cause prominent
changes in it. Upon treatment with glucose or glucosamine, com-
pounds that increase the amounts of hyaluronan substrates, the
HAS1 enzyme is able to produce significant amounts of hyaluro-
nan (12, 13). Furthermore, this effect of substrate availability on
HAS1 activity is dose dependent (12).
The above mentioned findings on the regulation of HAS1
activity point out that although HAS1 has a minor role in total cel-
lular hyaluronan production, it may have significant effects when
induced by increased substrate availability. Since the affinity of
HAS1 for its substrates is lower compared to the two other HAS’s,
the fluctuations in UDP–GlcNAc and UDP–GlcUA levels can have
a more significant effect on HAS1 than on HAS2–3.
HAS1 AS A MEDIATOR IN INFLAMMATION
Many recent results suggest HAS1 may play a pivotal role during
cell stress, such as inflammation. Earlier in this frontiers review
series, Petrey and de la Motte comprehensively discussed the role
of hyaluronan in inflammation (92). Whether hyaluronan acts
as a pro- or anti-inflammatory molecule is highly dependent
on its molecular size. Generally, low-molecular weight hyaluro-
nan fragments mediate pro-inflammatory responses (93) such as
recruitment of macrophages and other leukocytes to the injured
or inflamed tissue (94, 95) and stimulate transcription of genes
related to inflammation including several cytokines and matrix
metalloproteinases (96). Growth factors and pro-inflammatory
cytokines (Table 1) released during inflammation, like TGF-β, IL-
1β, and TNF-α, which stimulate inflammatory cells also induce
expression of HAS1 (44, 45, 64) and Has1 (97). Expression of
HAS1 is also upregulated in response to prostaglandins (98, 99).
Therefore, Has1/HAS1 up-regulation has been noted in many dis-
eases associated with inflammation such as murine atherosclerosis
(100), human osteoarthritis (101), murine infectious lung disease
(102), and human rheumatoid arthritis (45). HAS1 expression is
also increased, among several other genes, in osteophytic chondro-
cytes (103). Interestingly, the expression of both HAS1 and HAS2
was reduced in the synovium of patients with osteoarthritis or
rheumatoid arthritis compared to healthy controls (104). More-
over, elevated HAS1 expression is observed in oral lichen planus,
which is a chronic inflammatory disease of the oral mucosa (87).
It is worth noting that in oral lichen planus the increased HAS1
expression is detected in the basal layers of the epithelium, which
is the most affected, inflamed area in lichen planus.
It is not known whether the product of HAS1 enzyme of certain
polymer length, HAS1 enzyme itself or hyaluronan with HAS1
and hyaluronan binding proteins like CD44 mediate the pro-
inflammatory responses. One explanation for HAS1 involvement
in inflammation might be that HAS1 is associated with production
of a special type of pericellular hyaluronan coat, which is pro-
inflammatory. Recently, Siiskonen and co-workers showed that
inflammatory agents and glycemic stress induce HAS1 to pro-
duce an expanded pericellular hyaluronan coat (13). Compared to
Has3-induced hyaluronan coat, which is rather tight and formed
around microvillus protrusions (105), HAS1 produces a looser,
but extensive pericellular hyaluronan coat, which is dependent on
CD44. In several cell types, these types of hyaluronan coats have
been shown to associate with monocyte binding (106, 107). It has
even shown that hyaluronan produced by Has1 binds mononu-
clear cells more effectively than hyaluronan produced by the two
other Has enzymes (77). This could provide an explanation for the
central role of HAS1 in inflammation.
In rheumatoid arthritis, the rate of hyaluronan synthesis is
altered. Hyaluronan accumulates in joints affected by rheumatoid
arthritis, which causes periarticular swelling and morning stiffness
(108). In synoviocytes isolated from RA patients, HAS2 and HAS3
are constitutively activated, but HAS1 is the gene that responds
readily to pro-inflammatory cytokines like IL-1β (49) and TGF-
β (45). However, IL-1β is not able to stimulate Has1 expression
in healthy synoviocytes like in type-B synoviocytes isolated from
rheumatoid arthritis patients (49, 109). This IL-1β-induced HAS1
up-regulation is dependent on the activation of the transcription-
factor NF-κB (49), like many other pro-inflammatory molecules.
In type-B synoviocytes, IL-1β stimulation induces the transloca-
tion of NF-κB into the nucleus, which results in up-regulation
of HAS1 mRNA expression (49). Similarly, in fibroblast-like syn-
oviocytes, viral infection causes NF-κB activation and increased
HA release due to HAS1 up-regulation. This HAS1 up-regulation
is reversed with mitogen-activated protein kinase p38 and JNK
inhibitors indicating that viral RNA activates HAS1 through these
signaling pathways (110). Moreover, HAS1 activation is blocked
with commonly used anti-inflammatory drugs, hydrocortisone,
and dexamethasone, in TGF-β stimulated synoviocytes (51). In
these cells, glucocorticoids block p38 activation, which results in
suppressed HAS1 expression (51). Interestingly, sodium salicylate
inhibits IL-1β induced HAS1 activation and HA release in type-B
synoviocytes (64). This might explain some of the beneficial effects
of sodium salicylate in the treatment of rheumatoid arthritis.
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In addition to its role in rheumatoid inflammation, altered
HAS1 levels contribute to other inflammation-related states. In
murine models of asthma, Has1 mRNA is increased at an early
stage, but later decreased (111, 112). In thyroid dysfunction asso-
ciated with activation of the thyrotropin receptor, hyaluronan is
accumulated through up-regulation of HAS1 and HAS2 (113).
Taken together, HAS1 seems to be fundamentally involved in the
inflammatory processes. However, many questions are still waiting
for an answer.
HAS1 AS A PREDICTOR OF CANCER PROGRESSION
Hyaluronan content is known to be increased in many cancers,
which may be altered due to hyaluronan synthase expression.
Few studies have shown a direct association of HAS’s with can-
cer progression in vivo, but interestingly, HAS1 associates with
tumor progression and prognostic factors in many cases. Increased
expression of HAS1 is associated with poor patient survival in
ovarian cancer (114, 115), colon cancer (116), Waldenström’s
macroglobulinemia (21), and multiple myeloma (22). In multiple
myeloma and Waldenström’s macroglobulinemia, the occurrence
of HAS1 splice variants, rather than the full length HAS1, is
related to cancer prognosis. HAS1 expression is also increased
in bladder cancer, correlating with increased hyaluronan levels
(23), and predicting metastasis (117). In bladder cancer, HAS1 has
been shown to modulate HA and CD44 levels, affecting tumor
growth and progression (118). Accumulation of hyaluronan is
associated with poor patient survival in breast cancer (119, 120).
Recently, HAS1 and HA stainings were found to correlate with
each other in breast carcinoma cells of these tumors, and HAS1
was associated with estrogen receptor negativity, HER2 positivity,
high relapse rate, and short overall survival. In addition, expres-
sion levels of stromal HAS1 and HAS2 were related to obesity,
large tumor size, lymph node positivity, and estrogen receptor
negativity (8).
In serous ovarian tumors, HAS1 has been shown to be very low
or totally absent, whereas the levels of HAS2 and HAS3 mRNA
or staining levels are not elevated compared to normal ovaries or
benign tumors (83). Interestingly, the levels of HAS1 and HAS2
immunostainings are decreased in melanomas, correlating with
reduced hyaluronan content and poor overall survival observed in
these tumors (85, 121).
CONCLUSION AND FUTURE CHALLENGES
The hyaluronan coat produced by HAS1 differs from that of other
isoenzymes, as shown by fluorescent hyaluronan binding probes.
The flossy and loose coat is typical for cells with mesenchymal
origin, like fibroblasts, mesothelial cells, synovial fibroblasts, and
chondrocytes. Furthermore, as Table 1 summarizes, most of the
cells that respond to cytokines or growth factors by upregulating
Has1/HAS1 levels, are of the same mesenchymal origin. Addi-
tionally, these cell types secrete active proteoglycans and other
molecules participating in hyaluronan coat formation, like versi-
can, IαI, and TSG6, which are important players in inflammation
(92) and are associated with hyaluronan cables detected in fixed
cells. However, other HAS’s are active in these cells, and cell types
solely expressing HAS1 are not available, making it challenging to
study the specific contribution of HAS1. The most specific method
so far is the artificial overexpression of fluorescently tagged HAS1
in cells with low levels of HAS enzymes (12–14).
Interestingly, HAS1 overexpression in many epithelial cell types
has shown a low activity in normal culture conditions, without
addition of glucosamine or inflammatory cytokines. This suggests
that these cell types may lack factors that are crucial for HAS1
activity. Several studies suggest that HAS1 has a low capacity to
retain hyaluronan chains on the plasma membrane, thus other
molecules may be required to retain hyaluronan chains on the
plasma membrane and assemble the hyaluronan coat. A potential
molecule for these interactions is CD44, which seems to play a
special role in the formation of the HAS1-induced coat (13).
The complexity of hyaluronan metabolism, existence of three
isoenzymes, and the crucial role of HAS2 make it complicated
to study the biological effects of HAS1 in animal models. Further-
more, since most human tissues and cells express all HAS isoforms,
it is impossible to get comprehensive answers and make conclu-
sions on the role of a single isoenzyme. Furthermore, many cells
and tissues express low or negligible levels of HAS1 mRNA. How-
ever, variable sensitivity of the methods used and other limitations
may explain the low or absent HAS1 levels detected in some cases.
Several trials have been done to solve the function and reg-
ulation of this puzzling enzyme. Evidently, HAS1 is an impor-
tant regulator during inflammation and in states with altered
sugar metabolism. However, contradictory results raise several
new questions, which need to be resolved before we can elucidate
the exact role of HAS1.
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